Effect of varenicline on the acute and repeated locomotor responses to nicotine in rats

Synapse

Volumn 62, Issue 12, 2008, Pages 935-939

  Zaniewska, Magdalena ^a   McCreary, Andrew C ^b   Stefański, Roman ^c   Przegaliński, Edmund ^a   Filip, Małgorzata ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b Solvay Pharmaceuticals Inc   (Netherlands)

^c INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

Conditioned locomotion; Locomotor activity; Nicotine; Rat; Sensitization; Varenicline

Indexed keywords

NICOTINE; VARENICLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONDITIONING; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFICACY; INHIBITION KINETICS; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REINFORCEMENT; SENSITIZATION; TOBACCO DEPENDENCE; TREATMENT RESPONSE;

ANIMALS; BENZAZEPINES; DRUG ADMINISTRATION SCHEDULE; MALE; MOTOR ACTIVITY; NICOTINE; QUINOXALINES; RATS; RATS, WISTAR; RECEPTORS, NICOTINIC;

EID: 56549099171     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20564     Document Type: Article

References (32)

1. Aubin HJ, Bobak A, Britton JR, Oncken C, Billing CB Jr, Gong J, Williams KE, Reeves KR. Varenicline versus transdermal nicotine patch for smoking cessation: Results from a randomised, open-label trial. Thorax (in press).
2. Balfour DJ. 2002. Neuroplasticity within the mesoaccumbens dopamine system and its role in tobacco dependence. Curr Drug Targets CNS Neurol Disord 1:413-421.
3. Bolin K, Mörk AC, Willers S, Lindgren B. 2008. Varenicline as compared to bupropion in smoking-cessation therapy - Cost-utility results for Sweden 2003. Respir Med 102:699-710.
4. Carroll IF, Yokota Y, Wei M, Lee JR, Brieaddy LE, Burgess JP, Navarro HA, Damaj MI, Martin BR. 2008. Synthesis, nicotinic acetylcholine receptor binding, and pharmacological properties of 3′-(substituted phenyl) deschloroepibatidine analogs. Bioorg Med Chem 16:746-754.
5. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, Shrikhande A, Heym JH, Schaeffer E, Rollema H, Lu Y, Mansbach RS, Chambers LK, Rovetti CC, Schulz DW, Tingley FD III, O'Neill BT. 2005. Varenicline: An alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48:3474-3477.
6. DiFranza JR, Wellman RJ. 2005. A sensitization-homeostasis model of nicotine craving, withdrawal, and tolerance: Integrating the clinical and basic science literature. Nicotine Tob Res 7:9-26.
7. Dougherty PL. 2008. Varenicline: A new pharmaceutical approach to smoking cessation. Nurs Womens Health 12:66-69.
8. FDA. 2006. The FDA approves new drug for smoking cessation. FDA Consum Mag 40:29.
9. Frankowska M, Filip M, Przegaliński E. 2007. Effects of GABA(B) receptor ligands in animal tests of depression and anxiety. Pharmacol Rep 59:645-655.
10. Garwood CL, Potts LA. 2007. Emerging pharmacotherapies for smoking cessation. Am J Health Syst Pharm 64:1693-1698.
11. George T, Weinberger A. 2008. Monoamine oxidase inhibition for tobacco pharmacotherapy. Clin Pharmacol Ther 83:619-621.
12. Grottick AJ, Trube G, Corrigall WA, Huwyler J, Malherbe P, Wyler R, Higgins GA. 2000. Evidence that nicotinic alpha(7) receptors are not involved in the hyperlocomotor and rewarding effects of nicotine. J Pharmacol Exp Ther 294:1112-1119.
13. Kempsill FE, Pratt JA. 2000. Mecamylamine but not the alpha7 receptor antagonist alpha-bungarotoxin blocks sensitization to the locomotor stimulant effects of nicotine. Br J Pharmacol 131:997-1003.
14. Le Foll B, George TP. 2007. Treatment of tobacco dependence: Integrating recent progress into practice. CMAJ 177:1373-1380.
15. Le Foll B, Goldberg SR. 2005. Control of the reinforcing effects of nicotine by associated environmental stimuli in animals and humans. Trends Pharmacol Sci 26:287-293.
16. Mihalak KB, Carroll FI, Luetje CW. 2006. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol 70:801-805.
17. Neugebauer NM, Zhang Z, Crooks PA, Dwoskin LP, Bardo MT. 2006. Effect of a novel nicotinic receptor antagonist. N,N′-dodecane-1,12-diyl-bis- 3-picolinium dibromide, on nicotine self-administration and hyperactivity in rats. Psychopharmacology 184:426-434.
18. Picciotto MR, Caldarone BJ, King SL, Zachariou V. 2000. Nicotinic receptors in the brain. Links between molecular biology and behavior. Neuropsychopharmacology 22:451-465.
19. Przegaliński E, Filip M, Papla I, Siwanowicz J. 2001. Effect of serotonin (5-HT)1B receptor ligands on cocaine sensitization in rats. Behav Pharmacol 12:109-116.
20. Rahman S, Neugebauer NM, Zhang Z, Crooks PA, Dwoskin LP, Bardo MT. 2007. The effects of a novel nicotinic receptor antagonist N,N-dodecane-1,12-diyl-bis- 3-picolinium dibromide (bPiDDB) on acute and repeated nicotine-induced increases in extracellular dopamine in rat nucleus accumbens. Neuropharmacology 52:755-763.
21. Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, Lu Y, Mansbach RS, Mather RJ, Rovetti CC, Sands SB, Schaeffer E, Schulz DW, Tingley FD III, Williams KE. 2007. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52:985-994.
22. Smith JW, Mogg A, Tafi E, Peacey E, Pullar IA, Szekeres P, Tricklebank M. 2007. Ligands selective for alpha4beta2 but not alpha3-beta4 or alpha7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat. Psychopharmacology 190:157-170.
23. Stapleton JA, Watson L, Spirling LI, Smith R, Milbrandt A, Ratcliffe M, Sutherland G. 2008. Varenicline in the routine treatment of tobacco dependence: A pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 103:146-154.
24. Steensland P, Simms JA, Holgate J, Richards JK, Bartlett SE. 2007. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci USA 104:12518-12523.
25. Tonstad S, Tønnesen P, Hajek P, Williams KE, Billing CB, Reeves KR. 2006.Varenicline Phase 3 Study Group. Effect of establishment therapy with varenicline on smoking cessation: A randomized controlled trial. JAMA 296:64-71.
26. Walters CL, Brown S, Changeux JP, Martin B, Damaj MI. 2006. The beta2 but not alpha7 subunit of the nicotinic acetylcholine receptor is required for nicotine-conditioned place preference in mice. Psychopharmacology 184:339-344.
27. Watkins SS, Epping-Jordan MP, Koob GF, Markou A. 1999. Blockade of nicotine self-administration with nicotinic antagonists in rats. Pharmacol Biochem Behav 62:743-751.
28. West R, Baker CL, Cappelleri JC, Bushmakin AG. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology (in press).
29. Wilkinson JL, Palmatier MI, Bevins RA. 2006. Preexposure to nicotine alters the subsequent locomotor stimulant effects of bupropion in rats. Nicotine Tob Res 8:141-146.
30. Zaniewska M, McCreary AC, Przegaliński E, Filip M. 2006. Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats. Eur J Pharmacol 540:96-106.
31. Zaniewska M, Filip M, McCreary AC, Nowak E, Przegaliński E. 2007a. Effects of the serotonin 2C receptor ligands in the nicotine-evoked conditioned hyperlocomotion and sensitization. Eur Neuropsychopharmacol 17 (Suppl 1):S45.
32. Zaniewska M, McCreary AC, Przegaliński E, Filip M. 2007b. Effects of the serotonin 5-HT2A and 5-HT2C receptor ligands on the discriminative stimulus effects of nicotine in rats. Eur J Pharmacol 571:156-165.